In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
The Division of Antiviral products has laid out nonbinding recommendations about the acceptable NGS platforms and the kinds of information it's looking for.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
Danaher is offering 11 million shares of its common stock at $123 per share and 1.5 million shares of its mandatory convertible preferred stock at $1,000 per share.
Danaher is financing the deal with $3 billion from an equity offering, cash on hand, and proceeds from an issuance of debt and/or new credit facilities.
Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.
The Jamaican Lion strain was sequenced and assembled with DASH funding, and will be published via "crypto-incentivized, blockchain-recorded peer review."
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
